Program
insulin icodec
Also written as “Insulin icodec”, “Insulin Icodec” and “IcoSema”.
Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus, Type 1, led by Novo Nordisk.
Drug pageInsulin icodec: every studyAll 31 studies of it, academic ones too, with its approvals, label and forms.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Novo Nordisk | 302 open or running | phase 4since Aug 1, 2025 | Mar 8, 2013 | Jan 25, 2027phase 3 · NCT07076199 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.
Not listed one by one: 12 earlier studies, Mar 8, 2013 to Jul 6, 2020.
- Jun 9, 2020Named insulin icodecINNProposed as its International Nonproprietary Name in WHO's List 123 · before, NNC0148-0287
- Oct 8, 20203 phase 1 studies in Diabetes Mellitus, Type 2NCT04582448, NCT04582435, NCT04597697
- Feb 17, 20212 phase 3 studies in Diabetes Mellitus, Type 2NCT04760626, NCT04770532
- Mar 10, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04795531 · 588 enrolled · United States, Argentina, Austria and more
- Apr 16, 2021Phase 3 study in Diabetes Mellitus, Type 1NCT04848480 · 582 enrolled · United States, Austria, Canada and more
- Apr 22, 2021Phase 1 study in Diabetes Mellitus, Type 2NCT04857398 · 24 enrolled · China
- May 6, 2021Phase 3 study in Diabetes Mellitus, Type 2NCT04880850 · 582 enrolled · United States, Belgium, India and more
- Apr 24, 2022Phase 3 study in Diabetes Mellitus, Type 2NCT05352815 · 1,291 enrolled · United States, Australia, Belgium and more
- Jun 23, 2022Phase 1 study in Diabetes Mellitus, Type 2NCT05435677 · 20 enrolled · China
- Mar 17, 2023Phase 1 study in Diabetes Mellitus, Type 2NCT05790681 · 18 enrolled · United States
- Apr 3, 20232 phase 3 studies in Diabetes Mellitus, Type 2NCT05813912, NCT05823948
- Feb 23, 2024Phase 1 study in Diabetes Mellitus, Type 2NCT06288412 · 30 enrolled · Austria
- Mar 26, 2024Phase 3 study in Diabetes Mellitus, Type 2NCT06340854 · 412 enrolled · United States, Bulgaria, Germany and more
- Jul 14, 2025Phase 3 study in Diabetes Mellitus, Type 1NCT07076199 · 877 enrolled · United States, Australia, Canada and more
- Aug 1, 2025Phase 4 study in Diabetes Mellitus, Type 2NCT07112339 · 586 planned · Canada, Germany, Italy
Ahead
- Jan 25, 2027Primary completion: phase 3 study in Diabetes Mellitus, Type 1NCT07076199
- Mar 23, 2028Primary completion: phase 4 study in Diabetes Mellitus, Type 2NCT07112339
TargetBeta
“Insulin receptor agonist”ChEMBL 37, by rule
Other programs on INSR
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Insulin Glarginerule | Sanofi | phase 4 | 190 |
| Insulin Aspartrule | Novo Nordisk | phase 4 | 146 |
| insulin degludecrule | Novo Nordisk | phase 4 | 108 |
| Insulinrule | Pfizer | phase 4 | 50 |
| insulin glulisinerule | Sanofi | phase 4 | 43 |
| linsitinibrule | Astellas Pharma | phase 3 | 13 |
| LY3938577 | Eli Lilly | phase 2 | 3 |
Studies
All 30 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07112339Diabetes Mellitus, Type 2 · Canada, Germany, Italy | 4 | Recruiting | Mar 23, 2028 | 586 |
| NCT07076199Diabetes Mellitus, Type 1 · United States, Australia, Canada and more | 3 | Active, not recruiting | Jan 25, 2027 | 877 |
| NCT06340854Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more | 3 | Completed | May 8, 2025 | 412 |
| NCT06288412Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Mar 10, 2025 | 30 |
| NCT05823948Diabetes Mellitus, Type 2 · United States | 3 | Completed | Mar 6, 2024 | 51 |
| NCT05813912Diabetes Mellitus, Type 2 · Czechia, Malaysia, Poland and more | 3 | Completed | Apr 14, 2025 | 148 |
| NCT05790681Diabetes Mellitus, Type 2 · United States | 1 | Completed | Feb 8, 2024 | 18 |
| NCT05435677Diabetes Mellitus, Type 2 · China | 1 | Completed | Apr 25, 2023 | 20 |
| NCT05352815Diabetes Mellitus, Type 2 · United States, Australia, Belgium and more | 3 | Completed | Mar 19, 2024 | 1,291 |
| NCT04880850Diabetes Mellitus, Type 2 · United States, Belgium, India and more | 3 | Completed | Jun 16, 2022 | 582 |
| NCT04857398Diabetes Mellitus, Type 2 · China | 1 | Completed | Apr 6, 2022 | 24 |
| NCT04848480Diabetes Mellitus, Type 1 · United States, Austria, Canada and more | 3 | Completed | Apr 28, 2022 | 582 |
| NCT04795531Diabetes Mellitus, Type 2 · United States, Argentina, Austria and more | 3 | Completed | Jun 23, 2022 | 588 |
| NCT04770532Diabetes Mellitus, Type 2 · United States, Bulgaria, Germany and more | 3 | Completed | Jan 27, 2022 | 526 |
| NCT04760626Diabetes Mellitus, Type 2 · United States, Bulgaria, Canada and more | 3 | Completed | Aug 12, 2022 | 1,085 |
| NCT04597697Diabetes Mellitus, Type 2 · Czechia, Slovakia | 1 | Completed | Mar 24, 2022 | 25 |
| NCT04582448Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Sep 27, 2021 | 25 |
| NCT04582435Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Apr 22, 2022 | 46 |
| NCT04460885Diabetes Mellitus, Type 2 · United States, Croatia, India and more | 3 | Completed | May 29, 2022 | 984 |
| NCT03951805Diabetes Mellitus, Type 2 · United States, Croatia, Germany and more | 2 | Completed | Dec 12, 2019 | 205 |
| NCT03945656Diabetes Mellitus, Type 2 · Austria | 1 | Completed | Sep 27, 2021 | 43 |
| NCT03922750Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more | 2 | Completed | Dec 19, 2019 | 154 |
| NCT03789578Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Oct 10, 2019 | 30 |
| NCT03766854Diabetes Mellitus, Type 1 · Japan | 1 | Completed | Dec 9, 2019 | 24 |
| NCT03751657Diabetes Mellitus, Type 2 · United States, Canada, Czechia and more | 2 | Completed | Dec 16, 2019 | 247 |
| NCT03723785Diabetes Mellitus, Type 2 · Germany | 1 | Completed | Sep 6, 2019 | 58 |
| NCT03723772Diabetes Mellitus, Type 1 · Germany | 1 | Completed | Jun 26, 2020 | 66 |
| NCT02964104Diabetes Mellitus · Germany | 1 | Completed | Dec 12, 2017 | 50 |
| NCT02148861Diabetes Mellitus · Germany | 1 | Completed | Jun 1, 2015 | 49 |
| NCT01809184Diabetes Mellitus · Germany | 1 | Completed | Sep 6, 2013 | 84 |
How it is read
Names in the registry
- “Insulin icodec”, 18 entries
- “insulin icodec”, 5 entries
- “Insulin Icodec”, 4 entries
- “IcoSema”, 1 entry
- “NNC0148-0287”, 1 entry
Conditions, from the studies’ own filings
- Diabetes Mellitus, Type 2, 26 studies
- Diabetes Mellitus, Type 1, 4 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.